Dapagliflozin + Sliding scale insulin
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Hyperglycemia Steroid-induced
Conditions
Hyperglycemia Steroid-induced
Trial Timeline
Feb 1, 2015 → May 1, 2017
NCT ID
NCT02253121About Dapagliflozin + Sliding scale insulin
Dapagliflozin + Sliding scale insulin is a approved stage product being developed by AstraZeneca for Hyperglycemia Steroid-induced. The current trial status is completed. This product is registered under clinical trial identifier NCT02253121. Target conditions include Hyperglycemia Steroid-induced.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02253121 | Approved | Completed |
Competing Products
9 competing products in Hyperglycemia Steroid-induced
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Exenatide + Insulin | Eli Lilly | Phase 2/3 | 65 |
| Human regular insulin + Insulin lispro + Insulin glargine | Eli Lilly | Phase 3 | 77 |
| GLP-1 control + GLP-1 and Exendin(9-39) 300 + saline control + GLP-1 and Exendin(9-39) 600 + GLP-1 and Exendin(9-39) 900 + GLP-1 and Exendin(9-39) 1200 | Merck | Phase 1 | 33 |
| liraglutide + placebo | Novo Nordisk | Pre-clinical | 22 |
| Olanzapine + Ziprasidone | Pfizer | Pre-clinical | 22 |
| NPH insulin plus Complete Insulin Orders + Complete Insulin Orders | Sanofi | Approved | 84 |
| insulin glargine + insulin glargine + insulin glargine | Sanofi | Approved | 84 |
| Lantus® (insulin glargine) | Sanofi | Phase 1 | 32 |
| insulin glargine recombinant + therapeutic insulin | Sanofi | Phase 3 | 76 |